Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Phase 1 Completed
26 enrolled 24 charts
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
Phase 1 Completed
32 enrolled
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Phase 1 Completed
14 enrolled
A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
Phase 1 Completed
27 enrolled
Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)
Phase 1 Completed
32 enrolled
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
Phase 1 Completed
13 enrolled 12 charts
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
Phase 1 Completed
38 enrolled 14 charts
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Phase 1 Completed
27 enrolled 7 charts
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Phase 1 Completed
241 enrolled
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Phase 1 Completed
8 enrolled
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 Completed
12 enrolled 16 charts
5-AZA
Phase 1 Completed
3 enrolled
APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Phase 1 Completed
51 enrolled 9 charts
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
Phase 1 Completed
48 enrolled 85 charts
Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Phase 1 Completed
9 enrolled
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Phase 1 Completed
17 enrolled 33 charts
COZMOS
Phase 1 Completed
31 enrolled
OMNIVERSE
Phase 1 Completed
6 enrolled
BRIGHT 1012
Phase 1 Completed
73 enrolled 31 charts
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1 Completed
94 enrolled
A Study of Pevonedistat in Adult East Asian Participants
Phase 1 Completed
23 enrolled 23 charts
Pharmacokinetics, Tolerability and Safety of NEX-18a
Phase 1 Completed
2 enrolled
A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment
Phase 1 Completed
6 enrolled
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
Phase 1 Completed
62 enrolled
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 Completed
43 enrolled
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
Phase 1 Completed
21 enrolled
Window Trial 5-aza in HNSCC, T-tare
Phase 1 Completed
18 enrolled
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Phase 1 Completed
15 enrolled 10 charts
Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma
Phase 1 Completed
12 enrolled
AZACTA
Phase 1 Completed
5 enrolled
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma
Phase 1 Completed
59 enrolled
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
Phase 1 Completed
50 enrolled
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Phase 1 Completed
89 enrolled
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
Phase 1 Completed
3 enrolled
Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older
Phase 1 Completed
64 enrolled 38 charts
Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
Phase 1 Completed
8 enrolled
CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Phase 1 Completed
20 enrolled
RENAL
Phase 1 Completed
31 enrolled 30 charts
A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
Phase 1 Completed
19 enrolled
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Phase 1 Completed
169 enrolled
Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine
Phase 1 Completed
34 enrolled
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Phase 1 Completed
76 enrolled
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
Phase 1 Completed
133 enrolled
RACE
Phase 1 Completed
31 enrolled
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
Phase 1 Completed
63 enrolled
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Phase 1 Completed
63 enrolled
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
Phase 1 Completed
34 enrolled
VEOX
Phase 1 Completed
12 enrolled
Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Phase 1 Completed
5 enrolled 9 charts
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
Phase 1 Completed
52 enrolled